Short-Schedule Intravesical Gemcitabine with Ablative Intent in Recurrent Ta–T1, G1–G2, Low- or Intermediate-Risk, Transitional Cell Carcinoma of the Bladder-Reference-Cited by-同舟云学术

Short-Schedule Intravesical Gemcitabine with Ablative Intent in Recurrent Ta–T1, G1–G2, Low- or Intermediate-Risk, Transitional Cell Carcinoma of the Bladder

Published:2007-04 Issue:4 Volume:51 Page:956-961
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Maffezzini Massimo,Campodonico Fabio,Canepa Giorgio,Capponi Giacomo,Fontana Vincenzo

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. The natural history of bladder cancer: implications for therapy;Lee;Urol Clin North Am,2000

2. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer;Kiemeney;J Urol,1993

3. Prognostic factors for recurrence follow-up policies in treatment of superficial bladder cancer: report from British Medical Research Council Subgroup on superficial bladder cancer;Parmar;J Urol,1989

4. Bladder cancer;Maffezzini;Crit Rev Oncol Hematol,1998

5. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association–defined Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: A Phase 1b Study;European Urology Open Science;2024-04

2. Real-world efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer;Expert Opinion on Pharmacotherapy;2023-10-19

3. A Systematic Review and Meta-analysis of Chemoablation for Non–muscle-invasive Bladder Cancer;European Urology Focus;2022-12

4. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial;Urologic Oncology: Seminars and Original Investigations;2022-07

5. Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non–muscle-invasive Bladder Cancer—A Randomized Controlled Trial. Eur Urol 2020;78:856–62;European Urology;2021-05